Sudha Tallavajhula
Clinical Neurophysiology · Houston, TXNPI 1851595441
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. ZOLL Respicardia, Inc. accounts for 88.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $5,198 and has fallen 53.3% since, to $2,429 in 2025.
Across 57 payments — averaging $244.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$12K
- Jazz Pharmaceuticals Inc.$676
- Harmony Biosciences LLC$220
- Avadel CNS Pharmaceuticals, LLC$185
- Sumitomo Pharma America, Inc.$132
- Inspire Medical Systems, Inc.$110
- plus $290 from 8 others
What the payments were for
- Consulting fees$3,85028%
- Speaking & faculty fees$8,25059%
- Travel & lodging$260%
- Food & beverage$1,59311%
- Education$1951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 11 | $12,301 |
| Jazz Pharmaceuticals Inc. | 17 | $676 |
| Harmony Biosciences LLC | 5 | $220 |
| Avadel CNS Pharmaceuticals, LLC | 8 | $185 |
| Sumitomo Pharma America, Inc. | 2 | $132 |
| Inspire Medical Systems, Inc. | 1 | $110 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| Argenx US, Inc. | 2 | $57 |
| UCB, Inc. | 3 | $56 |
| Eisai Inc. | 2 | $35 |
| SK Life Science, Inc. | 1 | $32 |
| Otter Pharmaceuticals, LLC | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Aucta Pharmaceuticals, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$12,100
- APTIOM$115
- Inspire Upper Airway Stimulation System$110
How this compares
$13,914 in reported general payments places this provider in the 80th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 13 | $15,882 |
| VimpatLacosamide | 13 | $15,570 |
| Lacosamide | 97 | $15,170 |
| Levetiracetam | 154 | $9,054 |
| KeppraLevetiracetam | 11 | $5,174 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $2,373 |
| Oxcarbazepine | 20 | $2,193 |
| Clobazam | 18 | $821 |
| Clonazepam | 48 | $639 |
| Lamotrigine | 40 | $606 |
| Topiramate | 16 | $500 |
| Valproic AcidValproic Acid (As Sodium Salt) | 12 | $415 |
| Zolpidem Tartrate | 34 | $328 |
| Trazodone Hcl | 38 | $327 |
| Gabapentin | 56 | $288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat | $56 | $31,45226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 clinical neurophysiology providers in Texas.
Other clinical neurophysiology in Houston
- Thy NguyenHouston$133K
- Nora Vanegas ArroyaveHouston$82K
- Samden LhatooHouston$66K
- Omotola HopeHouston$63K
- Hina DaveHouston$48K
- Monika UmmatHouston$36K
- Victor LevinHouston$10K
- Shaun SmartHouston$9K
- Kristin BrownHouston$5K
- Jay GavvalaHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.